Sentences with phrase «purchase price for the stock»

Options can help you protect against risk, generate income, increase profits, lower your breakeven point, reverse your strategy without selling your stock, and even potentially let you set a purchase price for a stock below its current market price.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

Despite Icahn's verbal pummelling, most analysts have a Buy rating on the stock and target prices much higher than Icahn's offer to purchase the company for US$ 7 a share.

It is now quite common, should a stock collapse, for companies to lower the purchase price on options already granted to employees, in order to stem a mass exodus of talent.

Though the IPO only gave Rovio half the market value the company had hoped for ($ 900 million ($ 1.1 billion) instead of its anticipated $ 2 billion), stock bounced back when a bank backing the IPO started purchasing shares to «stabilize» the price, according to Bloomberg.

DQYDJ's stock return calculator tool, which gathers its numbers from data - platform Quandl, properly accounts for stock splits and special dividends by creating a «data structure [that] contains the initial purchase and the price fluctuations using stock closing prices on each day,» according to the site.

For example, if a $ 10 stock you purchased with cash rises in price by 10 percent, you have made a $ 1 profit.

Or establish a set of rules for when it's safe to purchase a new investment, such as a particular stock price - to - earnings threshold.

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

Stock options allow employees to purchase shares in their company at a price fixed when the optionis granted (the grant price) for a defined number of years into the future.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Another issue is that the bank usually advises that the company split its stock as many times as it needs to to get the price per share down to around $ 10 before it goes public, logic being that people like to buy in round lots (100 share purchases) and $ 1000 is a workable number for most people.

Camber Capital Management, a hedge fund with an activist history, has purchased 5.7 million shares of Tenet Healthcare Corp., or a 5.7 % stake in the money - losing hospital chain.The emergence of Camber was disclosed Monday, just three days after Tenet's largest shareholder, Glenview Capital Management, resigned two Tenet board seats, citing irreconcilable differences with management and the board.Glenview Capital, which owns an 18 % stake in Tenet, gave notice Friday that it would no longer participate in a stand - still agreement that had prevented it from launching a proxy fight for control of the company.Tenet investors welcomed the Camber disclosure Monday, driving up Tenet's stock price to $ 2.18, or 15 %, to $ 16.63 as of 12:30 p.m. ET.Tenet is the nation's third - largest investor - owned

However, Shares used to pay the exercise price or purchase price of an option or stock appreciation right or to satisfy tax withholding obligations relating to such awards do not become available for future issuance under the 2013 Plan.

From January 1, 2008 through December 31, 2010, the Registrant granted to its employees, consultants and other service providers options to purchase an aggregate of 12,566,833 shares of common stock under the Registrant's Amended and Restated 2003 Stock Incentive Plan, or the 2003 Plan, at exercise prices ranging from $ 1.50 to $ 14.46 per share, which includes options to purchase shares of common stock that were repriced on a one - for - one basis to $ 2.32 per share in February stock under the Registrant's Amended and Restated 2003 Stock Incentive Plan, or the 2003 Plan, at exercise prices ranging from $ 1.50 to $ 14.46 per share, which includes options to purchase shares of common stock that were repriced on a one - for - one basis to $ 2.32 per share in February Stock Incentive Plan, or the 2003 Plan, at exercise prices ranging from $ 1.50 to $ 14.46 per share, which includes options to purchase shares of common stock that were repriced on a one - for - one basis to $ 2.32 per share in February stock that were repriced on a one - for - one basis to $ 2.32 per share in February 2009.

Therefore, if you purchase shares of our Class A common stock in this offering, you will experience immediate dilution of $ per share, the difference between the price per share you pay for our Class A common stock and its pro forma net tangible book value per share as of September 30, 2010, after giving effect to the issuance of shares of our Class A common stock in this offering.

From January 1, 2008 through December 31, 2010, the Registrant granted to certain executive officers, directors and other investors options and rights to purchase an aggregate of 8,196,662 shares of common stock under the 2003 Plan at exercise prices ranging from $ 2.00 to $ 6.20 per share, which includes options to purchase shares of common stock that were repriced on a one - for - one basis to $ 2.32 per share in February 2009.

For example, if you purchased one stock of Facebook for $ 100 and Facebook's stock price rose 10 %, your stock would now be worth $ 1For example, if you purchased one stock of Facebook for $ 100 and Facebook's stock price rose 10 %, your stock would now be worth $ 1for $ 100 and Facebook's stock price rose 10 %, your stock would now be worth $ 110.

Shares used to pay the purchase price or satisfy tax withholding obligations of awards other than stock options or stock appreciation rights become available for future issuance under the 2013 Plan.

As an individual investor, the best thing you can do to ensure you pay an accurate price for your shares is to research a company before purchasing their stock, and analyze whether or not the market appears to be reasonable in its pricing.

From July 2012 through September 2012, the Registrant sold an aggregate of 20,164,210 shares of its Series D convertible preferred stock to 21 accredited investors at a purchase price of approximately $ 11.014 per share, for an aggregate purchase price of approximately $ 222.1 million.

But given the actual market conditions which remain in place, it's difficult to imagine just what investors are hoping for - and what they think their money is actually buying - when they purchase stocks at current prices.

2,816,100 shares of our Class A common stock issuable upon the exercise of options to purchase shares of our Class A common stock granted after September 30, 2015 under our 2015 Equity Incentive Plan, with an exercise price per share equal to the public offering price set forth on the cover page of the final prospectus for this offering;

Historically, for shareholders participating in the DRIP, American Stock Transfer & Trust Company, LLC (the «Plan Agent») used cash dividends to purchase shares of NHF in the secondary market when the price of NHF's shares, plus estimated brokerage commissions, was less than NAV, or distributed newly issued common shares when the price of NHF's shares, plus estimated brokerage commissions, was equal to or greater than NAV.

In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of Class A common stock in the open market for the purpose of preventing or retarding a decline in the market price of the Class A common stock while this offering is in progress.

In January 2014, we sold an aggregate of 1,332,640 shares of Series C preferred stock to a total of three accredited investors at a purchase price per share of $ 3.40893 for an aggregate purchase price of $ 4,542,876.

in the case of our directors, officers, and security holders, (i) the receipt by the locked - up party from us of shares of Class A common stock or Class B common stock upon (A) the exercise or settlement of stock options or RSUs granted under a stock incentive plan or other equity award plan described in this prospectus or (B) the exercise of warrants outstanding and which are described in this prospectus, or (ii) the transfer of shares of Class A common stock, Class B common stock, or any securities convertible into Class A common stock or Class B common stock upon a vesting or settlement event of our securities or upon the exercise of options or warrants to purchase our securities on a «cashless» or «net exercise» basis to the extent permitted by the instruments representing such options or warrants (and any transfer to us necessary to generate such amount of cash needed for the payment of taxes, including estimated taxes, due as a result of such vesting or exercise whether by means of a «net settlement» or otherwise) so long as such «cashless exercise» or «net exercise» is effected solely by the surrender of outstanding stock options or warrants (or the Class A common stock or Class B common stock issuable upon the exercise thereof) to us and our cancellation of all or a portion thereof to pay the exercise price or withholding tax and remittance obligations, provided that in the case of (i), the shares received upon such exercise or settlement are subject to the restrictions set forth above, and provided further that in the case of (ii), any filings under Section 16 (a) of the Exchange Act, or any other public filing or disclosure of such transfer by or on behalf of the locked - up party, shall clearly indicate in the footnotes thereto that such transfer of shares or securities was solely to us pursuant to the circumstances described in this bullet point;

In May 2015, we sold an aggregate of 1,367,187 shares of Series F preferred stock to a total of four accredited investors at a purchase price of $ 30.72 for an aggregate purchase price of $ 41,999,985.

In October 2014, we sold an aggregate of 2,394,569 shares of Series E preferred stock to a total of two accredited investors at a purchase price per share of $ 21.7158 for an aggregate purchase price of $ 51,999,981.

Between June 2013 and August 2013, the Registrant issued and sold to six accredited investors an aggregate of 19,433,258 shares of Series D convertible preferred stock, at a purchase price of $ 2.21 per share, for aggregate consideration of $ 42,999,970.

The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally can not be less than 100 % of the fair market value of our Class A common stock on the date of grant.

As a result of this dilution, investors purchasing shares of Class A common stock in this offering may receive significantly less than the full purchase price that they paid for the stock purchased in this offering in the event of liquidation.

In May 2009, we completed our Series E financing in which $ 50.0 million of proceeds was received for the purchase of 19,901,290 shares of Series E convertible preferred stock at a price of $ 2.51 per share.

In March 2016, we sold an aggregate of 334,471 shares of Series F preferred stock to a total of two accredited investors at a purchase price of $ 30.72 for an aggregate purchase price of $ 10,274,949.

In May 2016, we sold an aggregate of 22,780,982 shares of Series F preferred stock to a total of 97 accredited investors at a purchase price of $ 30.72 for an aggregate purchase price of $ 699,831,767.

In July 2014, we sold an aggregate of 1,013,085 shares of Series E preferred stock to a total of five accredited investors at a purchase price per share of $ 21.7158 for an aggregate purchase price of $ 21,999,951.

There have been 12 stock splits for McDonald's throughout the decades, meaning that 100 shares purchased at the IPO price would have been 74,360 shares worth over $ 5.7 million.

In December 2014, we sold an aggregate of 4,186,629 shares of Series E preferred stock to a total of three accredited investors at a purchase price of $ 21.7158 per share for an aggregate purchase price of $ 90,915,998.

In February 2016, we sold an aggregate of 5,696,615 shares of Series F preferred stock to a total of 14 accredited investors at a purchase price of $ 30.72 for an aggregate purchase price of $ 175,000,013.

In recognition of these achievements and to create incentives for future success, the Compensation Committee recommended, and the Board of Directors approved a grant to Mr. Musk of 10,067,960 options to purchase shares of our common stock at an exercise price of $ 2.21 per share representing 4 % of our fully - diluted share base as of December 4, 2009, with 1 / 4th of the shares subject to the option vesting immediately, and 1 / 48th of the shares subject to the option scheduled to vest each month thereafter over the next three years, assuming Mr. Musk's continued service to us through each vesting date.

In July 2015, we sold an aggregate of 3,678,383 shares of Series F preferred stock to a total of six accredited investors at a purchase price of $ 30.72 for an aggregate purchase price of $ 112,999,926.

The purchase price for shares of our Class A common stock purchased under our 2015 ESPP will be 85 % of the lesser of the fair market value of our Class A common stock on (i) the first trading day of the applicable offering period and (ii) the last trading day of each purchase period in the applicable offering period.

In November 2014, we sold an aggregate of 4,604,942 shares of Series E preferred stock to a total of five accredited investors at a purchase price per share of $ 21.7158 for an aggregate purchase price of $ 99,999,999.

In virtually all stock market companies that have done ESOPs in the last 20 years, the company sets up the ESOP trust, which borrows money to finance the purchase of newly issued shares, and the trust pays the market price on that day for the shares.

The 2014 Recapitalization Agreement would also provide that under certain circumstances we may be required to issue new warrants to purchase shares of our common stock at an exercise price per share of $ 0.01 rather than issue shares of our common stock, in exchange for certain of the Related - Party Notes and Related - Party Warrants.

During July 2011, we sold an aggregate of 10,097,159 shares of our Series G - 1 convertible preferred stock to two accredited investors at a purchase price of approximately $ 16.09 per share, for an aggregate purchase price of $ 162,499,987.

In the event of a change of control (as defined in the plan), the compensation committee may, in its discretion, provide for any or all of the following actions: (i) awards may be continued, assumed, or substituted with new rights, (ii) awards may be purchased for cash equal to the excess (if any) of the highest price per share of common stock paid in the change in control transaction over the aggregate exercise price of such awards, (iii) outstanding and unexercised stock options and stock appreciation rights may be terminated, prior to the change in control (in which case holders of such unvested awards would be given notice and the opportunity to exercise such awards), or (iv) vesting or lapse of restrictions may be accelerated.

outstanding warrants to purchase shares of our common stock, including our Related - Party Warrants, either (i) would be exchanged for shares of our common stock depending in part on the initial public offering price of this offering, (ii) would be exercised to the extent the exercise price per share provided for therein is less than the initial public offering price of this offering or (iii) would expire or otherwise be cancelled; and

Participants may be required to pay cash or other legal consideration to the Company at the time of a stock grant, but the 2014 Plan does not establish a minimum purchase price for shares awarded as stock grants.